Clinical comprehensive evaluation of potassium-competitive acid blockers

HUANG Linlang; HUANG Xiaofang; LIU Yanyan; QIN Yiwei; CHEN Xin; JI Bo

doi:10.6039/j.issn.1001-0408.2024.23.03

您当前的位置：

首页 >

文章列表页 >

Clinical comprehensive evaluation of potassium-competitive acid blockers

更新时间：2024-12-09

- Clinical comprehensive evaluation of potassium-competitive acid blockers
- ZHONGGUO YAOFANG Vol. 35, Issue 23, Pages: 2851-2857(2024)
- 作者机构：
  
  中国人民解放军南部战区总医院药剂科，广州　510010
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.23.03
  CLC： R975+.2;R573
- Published：15 December 2024，
  
  Received：16 July 2024，
  
  Revised：28 October 2024，
- 稿件说明：
移动端阅览
黄琳琅,黄笑芳,刘艳艳等.钾离子竞争性酸阻滞剂的临床综合评价 ^Δ[J].中国药房,2024,35(23):2851-2857.

HUANG Linlang,HUANG Xiaofang,LIU Yanyan,et al.Clinical comprehensive evaluation of potassium-competitive acid blockers[J].ZHONGGUO YAOFANG,2024,35(23):2851-2857.
黄琳琅,黄笑芳,刘艳艳等.钾离子竞争性酸阻滞剂的临床综合评价 ^Δ[J].中国药房,2024,35(23):2851-2857. DOI： 10.6039/j.issn.1001-0408.2024.23.03.

HUANG Linlang,HUANG Xiaofang,LIU Yanyan,et al.Clinical comprehensive evaluation of potassium-competitive acid blockers[J].ZHONGGUO YAOFANG,2024,35(23):2851-2857. DOI： 10.6039/j.issn.1001-0408.2024.23.03.

摘要

目的

对我国已上市的3种钾离子竞争性酸阻滞剂（P-CAB）进行临床综合评价，为医疗机构遴选新药、优化用药目录以及合理使用该类药物提供参考。

方法

收集并整理富马酸伏诺拉生片、替戈拉生片、盐酸凯普拉生片相关的临床应用指南、专家共识、药品说明书、药品注册资料（包括Ⅲ期临床试验）以及PubMed、中国知网等数据库的Meta分析/系统综述等相关文献资料，依据《中国医疗机构药品评价与遴选快速指南（第二版）》中药学特性、有效性、安全性、经济性、其他属性5个维度对三者进行量化综合评价。

结果

3种P-CAB的5个维度评分从高到低依次为富马酸伏诺拉生片（81.8分）、替戈拉生片（75.7分）、盐酸凯普拉生片（75.6分）。在药学特性、有效性、经济性及其他属性4个维度中，富马酸伏诺拉生片得分均最高；而安全性得分稍低。

结论

3种P-CAB均为强推荐，表现出良好的临床效用；其中，富马酸伏诺拉生片在药学特性、有效性、经济性方面更有优势。

Abstract

OBJECTIVE

To conduct a clinical comprehensive evaluation of potassium-competitive acid blockers （P-CAB） and provide reference for medical institutions to select new drugs， optimize drug catalogs， and use such drugs reasonably.

METHODS

clinical application guidelines， expert consensus， drug instructions， drug registration data （including phase Ⅲ clinical trials）， meta-analysis/systematic review of databases such as PubMed and CNKI related to Vonoprazan fumarate tablets， Tegorasen tablets， and Keverprazan hydrochloride tablets already on the market in China were collected and organized. Based on the

Quick Guidelines for Drug Evaluation and Selection in Chinese Medical Institutions

（

Second Edition

）， a comprehensive evaluation of the three P-CAB drugs was conducted from five dimensions: pharmaceutical characteristics， efficacy， safety， economy， and the other property.

RESULTS

The five dimensions of the three P-CAB were ranked from high to low as follows： Vonoprazan fumarate tablets （81.8 points）， Tegorasen tablets （75.7 points）， and Keverprazan hydrochloride tablets （75.6 points）. Among them， Vonoprazan fumarate tablets scored the highest in 4 dimensions of pharmaceutical properties， efficacy， economy， and the other property； but the safety score was slightly low.

CONCLUSIONS

The three types of P-CAB are comprehensively strongly recommended and demonstrated good clinical efficacy. Vonoprazan fumarate tablets have more advantages in terms of pharmaceutical properties， efficacy， and economy.

关键词

钾离子竞争性酸阻滞剂富马酸伏诺拉生片盐酸凯普拉生片替戈拉生片临床综合评价

Keywords

Vonoprazan fumarate tabletsKeverprazan hydrochloride tabletsTegorasen tabletsclinical comprehensive evaluation

references

中华医学会，中华医学会杂志社，中华医学会消化病学分会，等. 消化性溃疡基层诊疗指南：2023年[J]. 中华全科医师杂志，2023，22（11）：1108-1117.

Chinese Medical Association，Chinese Medical Association Publishing House，Chinese Society of Gastroentero- logy，et al. Primary care guide for peptic ulcer：2023[J]. Chin J Gen Pract，2023，22（11）：1108-1117.

赵志刚，董占军，刘建平. 中国医疗机构药品评价与遴选快速指南：第二版[J]. 医药导报，2023，42（4）：447-456.

ZHAO Z G，DONG Z J，LIU J P. A quick guideline for drug evaluation and selection in Chinese medical institutions：the second edition[J]. Her Med，2023，42（4）：447-456.

ECHIZEN H. The first-in-class potassium-competitive acid blocker，vonoprazan fumarate：pharmacokinetic and pharmacodynamic considerations[J]. Clin Pharmacokinet，2016，55（4）：409-418.

ZHOU L Y ，LU H，SONG Z Q ，et al.2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment[J].Chin Med J （Engl），2022，135（24）：2899-2910.

SMITH S M，BOYLE B，BRENNAN D，et al. The second Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of Helicobacter pylori infection in adult patients in Ireland[J]. Eur J Gastroenterol Hepatol，2024，36（8）：1000-1009.

Chinese Society of Gastroenterology，Cancer Collaboration Group of Chinese Society of Gastroenterology，Chinese Medical Association，et al. Guidelines for diagnosis and treatment of chronic gastritis in China：2022，Shanghai[J]. J Dig Dis，2023，24（3）：150-180.

中华消化杂志编辑委员会，邹多武，谢渭芬，等.消化性溃疡诊断与治疗共识意见：2022年，上海[J].胃肠病学，2023，28（4）：208-225.

Editorial Board of Chinese Journal of Digestion，ZOU D W，XIE W F，et al. Consensus on the diagnosis and treatment of peptic ulcer：2022，Shanghai[J]. Chin J Gastroenterol，2023，28（4）：208-225.

KAMADA T，SATOH K，ITOH T，et al. Evidence-based clinical practice guidelines for peptic ulcer disease 2020[J]. J Gastroenterol，2021，56（4）：303-322.

MORAES-FILHO J P P，DOMINGUES G，CHINZON D，et al. Brazilian clinical guideline for the therapeutic ma- nagement of gastroesophageal reflux disease （Brazilian federation of gastroenterology，FBG）[J]. Arq Gastroenterol，2024，61：e23154.

VALDOVINOS DÍAZ M A，AMIEVA-BALMORI M，CARMONA-SÁNCHEZ R，et al. Good clinical practice recommendations for the diagnosis and treatment of gastroesophageal reflux disease. An expert review from the Asociación Mexicana de Gastroenterología[J]. Rev Gastroenterol Mex （Engl Ed），2024，89（1）：121-143.

中华医学会消化病学分会胃肠动力学组，胃肠功能性疾病协作组，食管疾病协作组. 中国胃食管反流病诊疗规范[J]. 中华消化杂志，2023，43（9）：588-598.

Gastroenterology Group of Gastrointestinal Motility of the Chinese Medical Association，Gastrointestinal Functional Disease Cooperative Group，Esophageal Disease Cooperative Group. Chinese consensus on diagnosis and treatment of gastroesophageal reflux disease [J].Chin J Dig，2023，43（9）：588-598.

IWAKIRI K，FUJIWARA Y，MANABE N，et al. Evidence-based clinical practice guidelines for gastroeso- phageal reflux disease 2021[J]. J Gastroenterol，2022，57（4）：267-285.

XIAO Y L，ZHANG S T，DAI N，et al. Phase Ⅲ，randomised，double-blind，multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis[J]. Gut，2020，69（2）：224-230.

CHEN S F，LIU D L，CHEN H H，et al. The efficacy and safety of keverprazan，a novel potassium-competitive acid blocker，in treating erosive oesophagitis：a phase Ⅲ，randomised，double-blind multicentre study[J]. Aliment Pharmacol Ther，2022，55（12）：1524-1533.

LEE K J，SON B K，KIM G H，et al. Randomised phase Ⅲ trial：tegoprazan，a novel potassium-competitive acid blocker，vs. esomeprazole in patients with erosive oeso- phagitis[J]. Aliment Pharmacol Ther，2019，49（7）：864-872.

CASTELL D O，KAHRILAS P J，RICHTER J E，et al. Esomeprazole （40 mg） compared with lansoprazole （30 mg） in the treatment of erosive esophagitis[J]. Am J Gastroenterol，2002，97（3）：575-583.

RAGHUNATH A S，GREEN J R B，EDWARDS S J. A review of the clinical and economic impact of using esomeprazole or lansoprazole for the treatment of erosive esophagitis[J]. Clin Ther，2003，25（7）：2088-2101.

HARUMA K，KINOSHITA Y，YAO T，et al. Randomised clinical trial：3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis[J]. BMC Gastroenterol，2023，23（1）：139.

GONG H Y，HAN D，LIU S，et al. Adverse events of vonoprazan in the treatments of acid-related diseases：a systematic review and meta-analysis[J]. Rev Esp Enferm Dig，2023，115（6）：294-300.

TAN N D，MIAO X P，LIAO A J，et al. Efficacy and safety of keverprazan compared with lansoprazole in the treatment of duodenal ulcer：a phase Ⅲ，randomized，double-blind，multicenter trial[J]. Clin Transl Gastroenterol，2023，14（7）：e00602.

KIM J S，KO W，CHUNG J W，et al. Efficacy of tegoprazan-based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection：a randomized，double-blind，active-controlled study[J]. Helicobacter，2023，28（3）：e12977.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical comprehensive evaluation of recombinant Mycobacterium tuberculosis fusion protein

CHINA PH ARMACY Volume 33，Number 15，August 15，2022 Semimonthly Table of Contents Expert consensus on the comprehensive clinical evaluation of lipid-lowering drugs under the centralized drug volume-based procurement policy in Shandong Province

Related Author

ZHANG Hui

ZHANG Lingli

SHA Wei

LIN Minggui

CHU Naihui

SUN Feng

QIU Feng

CAI Benzhi

Related Institution

Dept. of Pharmacy， Changhai Hospital， Naval Medical University

Dept. of Tuberculosis， Shanghai Pulmonary Hospital Affiliated to Tongji University

Dept. of Infection， Beijing Tsinghua Changgung Hospital， Tsinghua University

Dept. of Tuberculosis， Beijing Chest Hospital， Capital Medical University

International Research Center for Medicinal Administration， Peking University

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰